Enzon PEG-ADA orphan product grant
Executive Summary
The "Severe Combined Immunogencity Disease: Enzyme Therapy" grant provides a total of $169,908 for a three year period to fund the on-going development of the orphan PEG-adenosine deaminase (PEG-ADA) for treatment of children with Severe Combined Immunodeficiency Disease (SCID). FDA designated PEG-ADA an orphan product in 1985.